Lymphoma Subtype Classification via Biomarker Expression Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for canine lymphoma, such as the PCR for Antigen Receptor Rearrangement test, cannot distinguish between lymphoma subtypes beyond simple T-cell versus B-cell phenotyping, limiting their ability to provide prognostically significant information for guiding therapy.
Innovation Solution
A method involving quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) is used to analyze the expression of biomarkers like CD28 and ABCA5 to differentiate between B-cell and T-cell lymphomas, and CCDC3 and SMOC2 to identify high-grade versus low-grade T-cell lymphomas, allowing for the classification of lymphomas into clinically relevant subtypes with high accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods like PCR for Antigen Receptor Rearrangement are used, then the diagnostic process is simple and cost-effective, but the ability to distinguish between lymphoma subtypes is limited
Solution Approach 1:
The diagnostic approach is segmented into two distinct stages: first using conventional PCR for Antigen Receptor Rearrangement to determine basic T-cell versus B-cell phenotyping, then applying qRT-PCR analysis of specific biomarker pairs (CD28/ABCA5 for cell lineage, CCDC3/SMOC2 for grade classification) only when subtype differentiation is needed. This segmentation allows the system to maintain simplicity for basic diagnostics while providing enhanced precision when required.
Solution Approach 2:
The patent applies local quality by using different diagnostic depths for different clinical needs. Basic phenotyping uses simple PCR methods, while subtype classification uses more complex qRT-PCR with specific biomarker ratios. The diagnostic intensity is locally optimized based on the specific information needed, avoiding unnecessary complexity in cases where simple phenotyping suffices.
2Reliability
If comprehensive biomarker analysis is performed to identify lymphoma subtypes, then prognostic information accuracy is improved, but the time and resources required for diagnosis increase
Solution Approach 1:
The patent performs preliminary phenotyping using PCR for Antigen Receptor Rearrangement to determine whether the lymphoma is T-cell or B-cell type before proceeding to more time-consuming qRT-PCR analysis. This preliminary action allows the diagnostic process to stop early if basic phenotyping provides sufficient information, or to proceed to detailed subtype classification only when necessary, thereby reducing overall diagnostic time while maintaining reliability.
Solution Approach 2:
The patent changes the analytical parameters based on the preliminary findings. After determining basic phenotyping through PCR, the system selectively applies qRT-PCR with specific biomarker pairs only when subtype differentiation is needed. This parameter change strategy avoids performing comprehensive biomarker analysis in all cases, thus reducing diagnostic time while maintaining prognostic reliability when detailed classification is required.
3Productivity
If simple phenotyping methods are used, then the diagnostic process is efficient and cost-effective, but prognostically significant information is lost
Solution Approach 1:
The diagnostic system is designed to be dynamic, adapting the level of analysis based on clinical needs. It can operate in a fast, cost-effective mode using simple PCR phenotyping when basic information suffices, or transition to a more comprehensive qRT-PCR based subtype classification when prognostic information is required. This dynamic approach optimizes both efficiency and information completeness based on the specific clinical scenario.
Solution Approach 2:
The patent creates a universal diagnostic system that can perform multiple functions: basic phenotyping, subtype classification, and prognostic assessment. By integrating both simple PCR methods and more sophisticated qRT-PCR analysis with specific biomarker pairs, the system provides a multi-functional solution that can deliver appropriate levels of diagnostic information efficiency depending on the clinical requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of lymphoma subtypes with at least 80% accuracy, providing prognostically significant information that can guide treatment decisions and improve diagnostic capabilities in a cost-effective and efficient manner, potentially applicable to human non-Hodgkin lymphomas as well.
Implementation Method 1
tumor tissue sample analysis can include qRT-PCR
Data Source
AI summary
A method for differentiating forms of lymphoma involves analyzing a tumor tissue sample from a subject for expression of CD28, ABCA5, CCDC3, and SMOC2. The CD28:ABCA5 expression ratio differentiates T-cell tumors from B-cell tumors. The CCDC3:SMOC2 expression ratio differentiates different T-cell tumors. The method can further include administering to the subject from whom the sample was obtained an appropriate treatment for the form lymphoma identified by performing the method.